NASDAQ:NEPH - Nephros Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.25
  • Forecasted Upside: 85.06 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$7.70
▲ +0.03 (0.39%)
1 month | 3 months | 12 months
Get New Nephros Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NEPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NEPH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$14.25
▲ +85.06% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Nephros in the last 3 months. The average price target is $14.25, with a high forecast of $16.00 and a low forecast of $12.50. The average price target represents a 85.06% upside from the last price of $7.70.
Buy
The current consensus among 2 investment analysts is to buy stock in Nephros. This rating has held steady since September 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/6/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/5/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/4/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/26/2021B. RileyInitiated CoverageBuy$12.50High
i
Rating by M. Wiesenberger at B. Riley
4/3/2020Maxim GroupReiterated RatingBuy$16.00Low
i
Rating by Anthony Vendetti at Maxim Group
2/29/2020Maxim GroupReiterated RatingBuy$16.00High
i
Rating by Anthony Vendetti at Maxim Group
1/7/2020Maxim GroupReiterated RatingBuy$16.00Medium
i
11/7/2019Maxim GroupReiterated RatingBuy$16.00High
i
10/24/2019BenchmarkInitiated CoverageBuy$16.00Low
i
10/4/2019Maxim GroupInitiated CoverageBuy$16.00High
i
4/24/2019Taglich BrothersReiterated RatingSpeculative BuyHigh
i
Rating by H. Halpern at Taglich Brothers
(Data available from 2/27/2016 forward)
Nephros logo
Nephros, Inc., a commercial-stage company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; hemodiafilters for use as dialyzers in hemodialysis treatment; and water filters to health care, food service, hospitality, and convenience store markets under the AETHER brand name. The company was founded in 1997 and is headquartered in South Orange, New Jersey.
Read More

Today's Range

Now: $7.70
$7.38
$7.87

50 Day Range

MA: $8.12
$7.67
$8.93

52 Week Range

Now: $7.70
$4.42
$10.00

Volume

31,766 shs

Average Volume

17,933 shs

Market Capitalization

$75.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Nephros?

The following sell-side analysts have issued research reports on Nephros in the last twelve months: B. Riley, Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for NEPH.

What is the current price target for Nephros?

2 Wall Street analysts have set twelve-month price targets for Nephros in the last year. Their average twelve-month price target is $14.25, suggesting a possible upside of 85.1%. Maxim Group has the highest price target set, predicting NEPH will reach $16.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $12.50 for Nephros in the next year.
View the latest price targets for NEPH.

What is the current consensus analyst rating for Nephros?

Nephros currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NEPH will outperform the market and that investors should add to their positions of Nephros.
View the latest ratings for NEPH.

What other companies compete with Nephros?

How do I contact Nephros' investor relations team?

Nephros' physical mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company's listed phone number is 201 343 5202. The official website for Nephros is www.nephros.com.